Rising Cost Of PrEP To Prevent HIV Infection Pushes It Out Of Reach For Many

Gilead Sciences makes Truvada, a medicine known generically as "pre-exposure prophylaxis," or PrEP. Consistent, daily doses of the drug are thought to reduce the risk of getting HIV from sex by more than 90 percent.

Many people at high risk for HIV can’t afford PrEP, though it’s more than 90 percent effective. The HIV medicine’s list price, close to $2,000 for a 30-day supply, has risen 45 percent in six years.

(Image credit: Paul Sakuma/AP)